Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition comprising

one or more purified flavonoids; and

purified menthol, in a state of purity such that the purified menthol has a direct antiviral effect in vitro on rhinovirus in WISH cells, or potentiates the antiviral effect in vitro of human interferon -α-2b (Intron A) on rhinovirus in WISH cells[[,]].

2. (Cancelled)

3. (Original) The pharmaceutical composition according to claim 1, wherein said composition also comprises a pharmaceutically acceptable metal complex and/or metal salt.

4. (Cancelled)

5.(Previously presented) The pharmaceutical composition according to claim 3, wherein said metal is zinc.

6.(Previously presented) The pharmaceutical composition according to claim 3, wherein the metal is zinc selected from the group consisting of Zn^{2+} aminochelates , Zn^{2+} amino acid chelates, $Zn(acetate)_2$, Zn^{2+} DL-methionine, Zn^{2+} L-methionine, ZnGluconate and PolaPreZinc ®.

7.(Original) The pharmaceutical composition according to

claim 1, wherein said composition is useful for oral and/or nasal administration.

8.(Original) The pharmaceutical composition according to claim 1, wherein said composition is selected from the group consisting of lozenges, troches, capsules, syrups, tablets, lollipops, solutions, dispersions, suspensions, powders, micropheres, chewing tablets, chewing gums, sprays, droppers, pipettes and pills.

9.(Original) The pharmaceutical composition according to claim 1, wherein said composition is a slow-release composition.

10.(Original) The pharmaceutical composition according to claim 1, wherein said composition is lozenges.

11.(Original) The pharmaceutical composition according to claim 1, wherein said composition is essentially free of crude plant extracts.

12.(Original) The pharmaceutical composition according to claim 1, wherein said composition is essentially free of other terpenes than menthol.

13.(Previously Presented) The pharmaceutical composition according to claim 1, wherein said composition is essentially free of one or more compounds selected from the group consisting of menthone, menthyl acetate, limonene and neomenthol.

14.(Original) The pharmaceutical composition according to

claim 1, wherein one or more flavonoids are chelating a metal.

15.(Original) The pharmaceutical composition according to claim 1, wherein the metal is Zn^{2+}.

16.(Original) The pharmaceutical composition according to claim 1, wherein the flavonoid is selected from the group consisting of flavonoids of the general formula:



and the general formula:



Wherein

R2' can be selected from: -H

-OH

R3' can be selected from: -H

-OH

-OCH_3

-OCH_2CH_2OH

R4′ can be selected from: -H

-OH

-OCH_3

-OCH_2CH_2OH

R5′ can be selected from: -H

-OH

-OCH_3

-OCH_2CH_2OH

R6′ is -H;

R3 including $R3_1$ and $R3_2$ can individually be selected from:

-H

-OH

-O-rutinose

-O-glucoside

-O-glucose-p-coumaric acid

-SOH

-O-rhamnose

R4 can be selected from: -(O)

-OH

R5 can be selected from: -H

-OH

-O-CH_2CH_2OH

R6 can be selected from: -H
-OH
$-OCH_3$

R7 can be selected from: -H
-OH
-O-glucose
$-OCH_3$
$-OCH_2CH_2OH$
-O-glucuronic acid
-O-rutinose
-O-rhamnoglucoside

R8 can be selected from: -H
-OH

17.(Original) The pharmaceutical composition according to claim 1, wherein the flavonoid is selected from the group consisting of troxerutin, venoruton, hesperitin, naringenin, nobiletin, tangeritin, baicalein, galangin, genistein, quercetin, apigenin, kaempferol, fisetin, rutin, luteolin, chrysin, taxifolin, eriodyctol, catecithin, epicatechin gallate, epigallocatechin gallate, flavone, sideritoflavone, hypolaetin-8-O-Gl, oroxindin, 3-hydroxyflavone, morin, quercetagetin-7-O-Gl, tambuletin, gossypin, hipifolin, naringin, leucocyanidol, amentoflavone and derivatives thereof and mixtures thereof

18.(Original) The pharmaceutical composition according to claim 1, wherein said flavonoid is not a naturally occurring flavonoid.

19.(Original) The pharmaceutical composition according to claim 1, wherein said flavonoid is a rutoside.

20.(Original) The pharmaceutical composition according to claim 1, wherein at least one flavonoid is a rutoside aglycone.

21.(Original) The pharmaceutical composition according to claim 1, wherein said flavonoid is a hydroxyethylrutoside.

22.(Original) The pharmaceutical composition according to claim 1, wherein at least one flavonoid is a hydroxyethythyrutoside aglycone.

23.(Original) The pharmaceutical composition according to claim 1, wherein said composition comprises a mixture of hydroxyethylrutosides.

24.(Original) The pharmaceutical composition according to claim 1, wherein said composition comprises a mixture of mono-, di-, tri- and tetrahydroxyethylrutosides.

25.(Original) The pharmaceutical composition according to claim 1, wherein at least one flavonoid is troxerutin.

26.(Original) The pharmaceutical composition according to claim 1, where at least one flavonoid is troxerutin aglycone.

27.(Original) The pharmaceutical composition according to claim 1, wherein the flavonoid is veneruton.

28-86. (Cancelled)

87. (Previously Presented) The pharmaceutical composition according to claim 1, wherein said purified menthol is at least 90% pure.

88. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the composition is in a form suitable for nasal administration.

89. (Previously Presented) The pharmaceutical composition according to claim 88, wherein the composition is in a form suitable for aerosol administration.

90. (Previously Presented) The pharmaceutical composition according to claim 89, wherein the composition is provided in a pressurized pack which further comprises a propellant.

91-97. (Cancelled)

98 (Previously Presented). The pharmaceutical composition according to claim 1, wherein said purified menthol is at least 98% pure.

99-109 (Cancelled).